Key Takeaways

Pfizer agreed to a deal with the Trump administration to lower some prescription drug costs

The agreement includes 'most-favored-nation' pricing for the Medicaid program and direct-sale website discounts

The pricing changes, which face skepticism, could take effect in 2026

WEDNESDAY, Oct. 1, 2025 (HealthDay News) — The White House has struck a deal with pharmaceutical giant Pfizer Inc. to lower the cost of prescription drugs for the Medicaid program.

The agreement — announced at the White House Tuesday by President Donald Trump and Pfizer CEO Albert Bourla — comes as the administration pushes for similar deals with other major drug manufacturers.

Under the terms of the deal, New York-based Pfizer will offer what the administration calls "most-favored-nation pricing"

See Full Page